A Phase III trial of RP-G28 to evaluate the efficacy, safety and durability of RP-G28 compared to a placebo in subjects with lactose intolerance.

Trial Profile

A Phase III trial of RP-G28 to evaluate the efficacy, safety and durability of RP-G28 compared to a placebo in subjects with lactose intolerance.

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs RP G28 (Primary)
  • Indications Lactose intolerance
  • Focus Registrational; Therapeutic Use
  • Sponsors Ritter Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2017 According to a Ritter Pharmaceuticals media release, the company raises $23 million to fund initiation of its Phase 3 clinical program in lactose intolerance.
    • 18 Aug 2017 According to a Ritter Pharmaceuticals media release, the phase III program consist of two confirmatory trials (this and 700287933) of similar trial design and size as the company's Phase IIb/3 trial [700253831]
    • 18 Aug 2017 According to a Ritter Pharmaceuticals media release, the Company has incorporated guidance from the FDA on key elements of its Phase 3 program following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top